Role of inflammation in bladder cancer pathogenesis - iBC
(HRZZ Research project)
Project leader: prof. dr. sc. Janoš Terzić
: 28.10.2015.- 27.10.2019.
prof. dr. sc. Marijan Šitum
prof. dr. sc. Ivan Đikić
, Goethe University School of Medicine, Frankfurt am Main, Germany
prof. dr. sc. Sergei Grivennikov, Fox Chase Cancer Center, Philadelphia, USA
Around 20% of cancer deaths are a consequence of chronic inflammation. Viral and bacterial infections, parasitic infestation, autoimmunity or chemical irritants cause inflammatory changes that stimulate cancer initiation, promotion and metastasis. We and others have shown that main molecular links between inflammation and cancer are cytokine IL-6 and its transcription factor STAT3. It is becoming obvious that microbiome composition of particular niche is important element of inflammation and cancer development. The role of inflammation in urinary bladder cancer (BC) pathogenesis is poorly understood although chronic inflammation caused by Schistosoma haematobioum
has pro-tumorigenic effect while acute inflammation induced by BCG is successfully used as a therapy for BC.
This project addresses fundamental questions of bladder cancerogensis. If altering STAT3 activity has inhibitory effect on BC development that finding can lead to new therapies (use of STAT3 inhibitors) for established BC. Findings generated by the microbiome analysis can lead to novel preventive measures (microbiota manipulation by antibiotics or vaccination).